S-488210/S-488211 clinical trials

DURvalumab in Combination With S-488210/S-488211 vAccine in Non-muscle Invasive Bladder CancEr

This study, called DURANCE, is testing a new combination treatment for bladder cancer that hasn't spread into the muscle. It combines a vaccine (S-488210/S-488211) with an immunotherapy drug (durvalumab) to see if it's safe and effective in people who haven't responded well to previous treatments.